Immune-mediated liver injury caused by checkpoint inhibitors: A case series and review of the literature.
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 agents, exhibit notable efficacy across various types of cancer. Nevertheless, they can trigger immune-related adverse events, among which immune-mediated liver injury (ILICI) occurs in 5-10% of patients. Corticosteroids are currently recommended...